HomeCompanies › RNAC

Cartesian Therapeutics

Most recent annual filing: 2026-03-09

Catalyst timeline

5 trackedQuarter catalyst calendar →
  1. Descartes-08 AURORA topline1Q 2027Descartes-08 AURORA topline, 1Q 2027, thesis-defining
  2. Descartes-08 HELIOS readout1H 2027Descartes-08 HELIOS readout, 1H 2027, notable
  3. Cartesian Therapeutics corporate update2027Cartesian Therapeutics corporate update, 2027, routine
  4. Cartesian Therapeutics corporate financing1H 2027Cartesian Therapeutics corporate financing, 1H 2027, routine
  5. Descartes-08 TRITON pivotal interimmid-to-late 2027Descartes-08 TRITON pivotal interim, mid-to-late 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (4 active programs)

Technology platforms

tLNP · WestGene BioPharma

Targeted lipid nanoparticle (tLNP) delivery platform owned by WestGene BioPharma; used to deliver mRNA payloads in vivo for BCMA-directed T-cell engineering; focus area: autoimmune diseases including myasthenia gravis

Targets: BCMA

tLNPs · WestGene BioPharma

WestGene's proprietary targeted lipid nanoparticles platform for in vivo mRNA delivery; used to deliver Cartesian's mRNA payloads including anti-BCMA CAR constructs for in vivo CAR-T engineering in autoimmune diseases; focus on eliminating ex vivo manufacturing

Targets: BCMA

Discontinued (1)

Biotech Distilled coverage (4)

Articles open on Substack. Some deep dives are subscriber-only.